AG
Argenica Therapeutics Ltd
AGN.AX · ASX
$0.13 -7.14% (-$0.01)
1M -25.71%
Market Cap $16.7M
P/E Ratio -
Div. Yield -
ROE 18.34%
Bulios Fair Price
$0.07
46.2% downside
Current Price
$0.13
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AGN.AX is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
70 /100
Cheap P/B 2.83x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining Book val. growth 8.35%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 30.59%
Asset turnover 0.00x
ROE 18.34%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 10.60x
Int. coverage N/A
Stability
54 /100
Moderate Beta 0.78x
Profitable years 0
EPS volatility 47.84%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AGN.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Liz Dallimore
Employees
7
Headquarters
Nedlands
Upcoming events
02 MAR
Earnings
Upcoming earnings report